II. Preparations (Norgestimate / Ethinyl Estradiol)
- Ortho Tri-Cyclen (0.18 - 0.215 - 0.250 / 35)
III. Components
- Norgestimate 0.5 to 1.0 (see preparations above)
- Ethinyl Estradiol 35 ug
IV. Effect
- Relative Progestational Activity: 0.3 (low)
- Estrogenic Activity: 35 (moderate)
- Androgenic Activity: 0.15 (low)
V. Pill associated problems
- Indications to switch to Modicon
- Acne Vulgaris (lower androgen)
- Increased Appetite (lower Progestin)
- Break-through bleed days 1-9 (more Estrogen)
- Break-through bleed all of month (more Estrogen)
- Major Depression provoked (lower Progestin)
- Menses too light (more Estrogen, less Progestin)
- Indications to switch to Demulen 1/35
- Breast Tenderness or engorgement (lower Estrogen)
- Break-through bleed days 10-21 (more Progestin)
- Headaches (lower Estrogen)
- Heavy Menses (more Progestin or less Estrogen)
- Dysmenorrhea or Menstrual Cramps (more Progestin)
- Moodiness (less Estrogen or more Progestin)
- Weight gain (less Estrogen or more Progestin)
- Indications to switch to Lo/Ovral
- Libido decreased (more androgen)
VI. References
- Cerel-Suhl (1999) Am Fam Physician 60(7):2073 [PubMed]
- Speroff (1993) Obstet Gynecol 81:1034-47 [PubMed]
- Dickey (1998) Managing Contraceptive Pill Patients
Images: Related links to external sites (from Bing)
Related Studies
| tri-sprintec (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| TRI-SPRINTEC TABLET | Generic | $0.14 each |